Az interleukin-6-expresszió vizsgálata colorectalis adenocarcinomában szenvedő betegeken

Osszefoglalo. Bevezetes: A gyulladasos folyamatok es a tumorok kialakulasa, illetve progresszioja kozotti osszetett kapcsolat ismert. Az interleukin-6 (IL6) egy pleiotrop gyulladasos citokin, melynek tumorstimulalo es -gatlo tulajdonsaga is van. Celkitűzes: Kutatasunk celja az IL6-expresszio vizsgalata volt colorectalis adenocarcinoma miatt reszekcion atesett betegek szovettani metszetein. Modszer: Az Uzsoki Utcai Korhazban 2004 es 2011 kozott reszekalt 64, colorectalis tumoros beteg demografiai, sebeszeti es patologiai adatait gyűjtottuk ossze. A betegek szovettani metszeteit IL6-antitesttel festettuk. A digitalizalt metszeteket kvantitativ szinelemzessel kiertekeltuk, majd az eredmenyeket a betegek klinikai parametereinek fuggvenyeben elemeztuk. Eredmenyek: Előrehaladott stadiumu betegekben a tumorsejtek IL6-expresszioja szignifikansan magasabbnak bizonyult linearis regresszioval. A tumorsejtek IL6-expresszioja azonban nem korrelalt a nemmel, az eletkorral vagy a tumor differencialtsagaval. Megbeszeles: Kulonbsegek mutatkoztak a tumorsejtek es a stromasejtek IL6-kifejeződese kozott. Kovetkeztetes: Az IL6 hasznos marker es potencialis terapias cel lehet az előrehaladottabb stadiumu colorectalis tumoros betegeknel. Orv Hetil. 2021; 162(37): 1502-1507. SUMMARY INTRODUCTION It is well known that there is a complex correlation between inflammation and tumor development and tumor progression. Interleukin-6 (IL6) is a pleiotropic inflammatory cytokine with both tumor stimulating and inhibiting effect. OBJECTIVE The goal of our study was to evaluate the IL6 expression of histological slides from patients after resection of colorectal adenocarcinoma. METHOD Demographical, surgical, and pathological findings of 64 patients with colorectal cancer operated between 2004 and 2011 in Uzsoki Teaching Hospital were evaluated. Histopathological slides were stained with IL6 antibody. The digitalized slides were assessed with quantitative color analysis, and the results were evaluated according to patients' clinical parameters. RESULTS Linear regression showed significantly higher IL6 expression in the tumor cells in patients with advanced stages. However, the IL6 expression of the tumor cells did not correlate with sex, age, or tumor grade. DISCUSSION There were differences between the IL6 expression in tumor cells and stromal cells. CONCLUSION IL6 may be a useful marker and potential therapeutic target in patients with advanced colorectal cancer. Orv Hetil. 2021; 162(37): 1502-1507.